Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Clinical trial NCT04093596 · COMPLETED
Trial details
- NCT number
- NCT04093596
- Sponsor
- Allogene Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-23
- Primary completion
- 2025-01-27
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.